Bioengineers at the University of California, San Diego have developed an electrical graphene chip capable of detecting mutations in DNA. Researchers say the technology could one day be used in various medical applications such as blood-based tests for early cancer screening, monitoring disease biomarkers and real-time detection of viral and microbial sequences.
Washington State University researchers have developed a portable biosensor that makes it easier to detect harmful bacteria.
New generation of full sized fingerprint sensors has been unveiled by NEXT Biometrics Group. The low-power fingerprint sensors are not only cost-effective but are also robust.
In minuscule amounts, it works in cells as an essential catalyst called a cofactor and as a signaling molecule to trigger other processes. Now, for the first known time, researchers have tracked those activities inside of cells.
Profusa, Inc. announced today that it was selected by Pioneers, the global business relationship builder, to showcase the company's "wear-and-forget" Lumee™ biosensor technology at the Pioneers Festival held at the prestigious Hofburg Imperial Palace in Vienna, Austria, May 24th-25th.
Many cancers could be successfully treated if the patient consulted the doctor sufficiently early. But how can a developing cancer be detected if it doesn't give rise to any symptoms? In the near future, suitably early diagnosis could be provided by simple and cheap chemical sensors - thanks to special recognizing polymer films developed at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw.
Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that the National Institutes of Health has awarded it a $1.75 million grant under the Small Business Innovation Research (SBIR) program. Administered by the National Heart, Lung, and Blood Institute (NHLBI), the funding will support Fast-tracked Phase I and Phase II studies of the company's Lumee™ tissue-integrated biosensors for continuous monitoring of oxygen toward improving the clinical outcomes of patients suffering from peripheral artery disease (PAD).
Rice University synthetic biologist Jeffrey Tabor is intent upon making the gut check standard operating procedure.
Mitochondrial dysfunction plays a critical role in the development of chemical and pharmaceutical toxicity. However, current methods to evaluate mitochondrial activity still rely on traditional tests called end-point assays, which provide limited prognostic information.
Scientists of the Research Center caesar in Bonn, an Institute of the Max Planck Society, developed a new biosensor, which allows to measure nanomolar levels of the second messenger cAMP. The sensor makes it possible to study cAMP signaling with high precision, even in subcellular compartments. Using this new biosensor, the scientists of the Minerva Max Planck Research Group “Molecular Physiology“ headed by Dagmar Wachten and of the Department “Molecular Sensory Systems” headed by Benjamin Kaupp revealed how the production of cAMP is regulated in the flagella of sperm cells from mice.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.